News

InvestorsHub on MSN6d
ORIC Pharmaceuticals Shares Rally 20% on Encouraging Cancer Drug Trial and Funding Update
Shares of ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) jumped 20% following the release of early data from its ongoing Phase 1b ...
Investing6d
Cantor Fitzgerald maintains Overweight on ORIC Pharmaceuticals stock
On Thursday, Cantor Fitzgerald reiterated its Overweight rating on shares of ORIC Pharmaceuticals (NASDAQ: ORIC), currently trading at $5.97, following the company’s announcement of promising ...
Investing.com India5d
ORIC Pharmaceuticals shares surge on promising trial data
Cantor Fitzgerald analyst Prakhar Agrawal commented on the results, stating, "Overall, a solid update by ORIC with not much to nitpick on efficacy/safety." Agrawal reiterated an Overweight rating on ...
Seeking Alpha4mon
ORIC Pharmaceuticals: Too Early To Commit, Despite Some Good Early Data
ORIC Pharmaceuticals' ORIC-533 was promising ... In February last year, analysts at Cantor Fitzgerald noted that the global addressable market for ORC-114 was over $2.5bn, excluding China.
Cantor Fitzgerald to acquire UBS hedge fund unit, expanding alternative assets
U.S. brokerage firm Cantor Fitzgerald has agreed to buy UBS' hedge fund unit, it was announced on Wednesday, expanding Cantor ...
Investing3mon
Cantor Fitzgerald maintains Overweight on ORIC stock
On Monday, Cantor Fitzgerald reiterated its Overweight rating on ORIC Pharmaceuticals (NASDAQ:ORIC), currently trading at $13.39, after an incident involving a potential news leak. According to ...